Literature DB >> 25694246

Active Surveillance for Adverse Events Within 90 Days: The Standard for Reporting Surgical Outcomes After Pancreatectomy.

Lilian Schwarz1, Morgan Bruno1, Nathan H Parker1, Laura Prakash1, Yoshihiro Mise1, Jeffrey E Lee1, Jean-Nicolas Vauthey1, Thomas A Aloia1, Claudius Conrad1, Jason B Fleming1, Matthew H G Katz2.   

Abstract

BACKGROUND: The rate of adverse events after pancreatectomy is widely reported as a measure of surgical quality. However, morbidity data are routinely acquired retrospectively and often are reported at 30 days. The authors hypothesized that morbidity after pancreatectomy is therefore underreported. They sought to compare rates of adverse events calculated at multiple time points after pancreatectomy.
METHODS: The authors instituted an active surveillance system to detect, categorize, and grade the severity of all adverse events after pancreatectomy, using the modified Accordion system and International Study Group of Pancreatic Surgery definitions. All patients and clinical events were monitored directly for at least 90 days after surgery.
RESULTS: Of 315 consecutively monitored patients, 239 (76 %) experienced 500 unique adverse events. The absolute number of unique adverse events increased by 32 % between index discharge and 90 days and by 10 % between 30 and 90 days. The number of severe adverse events increased by 96 % between discharge and 90 days and by 29 % between 30 and 90 days. In this study, 16 % of the patients experienced at least one severe adverse event within the index hospitalization, 24 % within 30 postoperative days, and 29 % within 90 days. Among the 80 readmissions that occurred within 90 days, 28 (35 %) occurred later than 30 days after pancreatectomy.
CONCLUSIONS: Approximately one-third of severe adverse events and readmissions are reported more than 30 days after surgery. All adverse events that occur within 90 days of surgery must be identified and reported for accurate characterization of the morbidity associated with pancreatectomy.

Entities:  

Mesh:

Year:  2015        PMID: 25694246     DOI: 10.1245/s10434-015-4437-z

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  15 in total

1.  Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality.

Authors:  Jason W Denbo; Morgan L Bruno; Jordan M Cloyd; Laura Prakash; Jeffrey E Lee; Michael Kim; Christopher H Crane; Eugene J Koay; Sunil Krishnan; Prajnan Das; Bruce D Minsky; Gauri Varadhachary; Rachna Shroff; Robert Wolff; Milind Javle; Michael J Overman; David Fogelman; Thomas A Aloia; Jean-Nicolas Vauthey; Jason B Fleming; Matthew H G Katz
Journal:  J Gastrointest Surg       Date:  2016-10-11       Impact factor: 3.452

2.  Postoperative pancreatic fistula after distal pancreatectomy for non-pancreas retroperitoneal tumor resection.

Authors:  Emily Z Keung; Elliot A Asare; Yi-Ju Chiang; Laura R Prakash; Nikita Rajkot; Keila E Torres; Kelly K Hunt; Barry W Feig; Janice N Cormier; Christina L Roland; Matthew H G Katz; Jeffrey E Lee; Ching-Wei D Tzeng
Journal:  Am J Surg       Date:  2019-11-30       Impact factor: 2.565

3.  Risk-stratified clinical pathways decrease the duration of hospitalization and costs of perioperative care after pancreatectomy.

Authors:  Jason W Denbo; Morgan Bruno; Whitney Dewhurst; Michael P Kim; Ching-Wei Tzeng; Thomas A Aloia; Jose Soliz; Barbara Bryce Speer; Jeffrey E Lee; Matthew H G Katz
Journal:  Surgery       Date:  2018-05-25       Impact factor: 3.982

4.  Selective Perioperative Administration of Pasireotide is More Cost-Effective Than Routine Administration for Pancreatic Fistula Prophylaxis.

Authors:  Jason W Denbo; Rebecca S Slack; Morgan Bruno; Jordan M Cloyd; Laura Prakash; Jason B Fleming; Michael P Kim; Thomas A Aloia; Jean-Nicolas Vauthey; Jeffrey E Lee; Matthew H G Katz
Journal:  J Gastrointest Surg       Date:  2017-01-03       Impact factor: 3.452

5.  Prognostic significance of preoperative and postoperative CA 19-9 normalization in pancreatic adenocarcinoma treated with neoadjuvant therapy or surgery first.

Authors:  Timothy P DiPeri; Timothy E Newhook; Laura R Prakash; Naruhiko Ikoma; Jessica E Maxwell; Michael P Kim; Jeffrey E Lee; Matthew H G Katz; Ching-Wei D Tzeng
Journal:  J Surg Oncol       Date:  2022-06-20       Impact factor: 2.885

6.  Association of Patient Controlled Analgesia and Total Inpatient Opioid Use After Pancreatectomy.

Authors:  Russell G Witt; Timothy E Newhook; Laura R Prakash; Morgan L Bruno; Elsa M Arvide; Whitney L Dewhurst; Naruhiko Ikoma; Jessica E Maxwell; Michael P Kim; Jeffrey E Lee; Matthew H G Katz; Ching-Wei D Tzeng
Journal:  J Surg Res       Date:  2022-03-17       Impact factor: 2.417

7.  One-Year Postoperative Mortality in MEN1 Patients Operated on Gastric and Duodenopancreatic Neuroendocrine Tumors: An AFCE and GTE Cohort Study.

Authors:  Niki Christou; Muriel Mathonnet; Sébastien Gaujoux; Guillaume Cadiot; Sophie Deguelte; Jean-Louis Kraimps; Jean-Christophe Lifante; Fabrice Menegaux; Eric Mirallié; Fabrice Muscari; Bruno Carnaille; François Pattou; Alain Sauvanet; Pierre Goudet
Journal:  World J Surg       Date:  2019-11       Impact factor: 3.352

8.  Systemic therapy without radiation may be appropriate as neoadjuvant therapy for localized pancreas cancer.

Authors:  Scott Kizy; Ariella M Altman; Keith M Wirth; Schelomo Marmor; Jane Y C Hui; Todd M Tuttle; Emil Lou; Khalid Amin; Jason W Denbo; Eric H Jensen
Journal:  Hepatobiliary Surg Nutr       Date:  2020-06       Impact factor: 7.293

9.  Communicating Value: Use of a Novel Framework in the Assessment of an Enhanced Recovery Initiative.

Authors:  Casey J Allen; Nikhil G Thaker; Laura Prakash; Brittany C Kruse; Thomas W Feeley; Robert S Kaplan; Ryan Huey; Steven J Frank; Thomas A Aloia; Vijaya Gottumukkala; Matthew H G Katz
Journal:  Ann Surg       Date:  2021-01-01       Impact factor: 13.787

10.  Comparing Postoperative Complications and Inflammatory Markers Using Total Intravenous Anesthesia Versus Volatile Gas Anesthesia for Pancreatic Cancer Surgery.

Authors:  Jose M Soliz; Ifeyinwa C Ifeanyi; Mathew H Katz; Jonathan Wilks; Juan P Cata; Thomas McHugh; Jason B Fleming; Lei Feng; Thomas Rahlfs; Morgan Bruno; Vijaya Gottumukkala
Journal:  Anesth Pain Med       Date:  2017-08-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.